公开(公告)号：US20210198256A1

公开(公告)日：2021-07-01

申请号：US17192634

申请日：2021-03-04

Applicant: C4 Therapeutics, Inc.

Inventor： Christopher G. Nasveschuk ,  Ning Yin ,  Katrina L. Jackson ,  Gesine Kerstin Veits ,  Moses Moustakim ,  Jeremy L. Yap ,  Rhamy Zeid

IPC: C07D471/04 ,  C07D401/14 ,  C07D417/14

Abstract: Compounds that degrade BRD9 or MTH1 via the ubiquitin proteasome pathway in a subject in need thereof for therapeutic applications are provided. The compounds provided have an E3 Ubiquitin Ligase targeting moiety (Degron) that is linked to a Targeting Ligand for BRD9 or MTH1.

公开(公告)号：US20240398959A1

公开(公告)日：2024-12-05

申请号：US18642602

申请日：2024-04-22

Applicant: C4 THERAPEUTICS, INC.

Inventor： Andrew J. Phillips ,  Christopher G. Nasveschuk ,  James A. Henderson ,  Yanke Liang ,  Minsheng He ,  Kiel Lazarski ,  Gesine Kerstin Veits ,  Harit U. Vora

IPC: A61K47/54 ,  A61K31/45 ,  A61K31/451 ,  A61K31/454 ,  A61K31/4545 ,  C07D211/86 ,  C07D211/88 ,  C07D211/90 ,  C07D221/22 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08 ,  C07D487/04 ,  C07D495/04 ,  C07D495/14 ,  C07D519/00 ,  C07K14/47 ,  C07K14/72

Abstract: This invention provides Degronimers that have carbon-linked E3 Ubiquitin Ligase targeting moieties (Degrons), which can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.

公开(公告)号：US12049464B2

公开(公告)日：2024-07-30

申请号：US17901775

申请日：2022-09-01

Applicant: C4 Therapeutics, Inc.

Inventor： Christopher G. Nasveschuk ,  Rhamy Zeid ,  Ning Yin ,  Katrina L. Jackson ,  Gesine Kerstin Veits ,  Moses Moustakim ,  Jeremy L. Yap

IPC: C07D471/04 ,  A61P35/00 ,  C07D401/14

CPC classification number: C07D471/04 ,  A61P35/00 ,  C07D401/14

Abstract: BRD9 protein degradation compounds or pharmaceutically acceptable salts thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.

公开(公告)号：US20240245677A1

公开(公告)日：2024-07-25

申请号：US18600097

申请日：2024-03-08

Applicant: C4 THERAPEUTICS, INC.

Inventor： Katrina L. Jackson ,  Christopher G. Nasveschuk ,  Rhamy Zeid ,  Ning Yin ,  Gesine Kerstin Veits ,  Moses Moustakim ,  Jeremy L. Yap ,  Minsheng He ,  Robert T. Yu ,  Matthew J. Schnaderbeck ,  Kathleen Neville ,  Siyi Jiang ,  Meiqi Li ,  Qianwei Liu ,  Manjie Zheng ,  Jia Li ,  Liwei Zhang

IPC: A61K31/496 ,  A61P35/00

CPC classification number: A61K31/496 ,  A61P35/00

Abstract: Selected BRD9 protein degradation compounds and morphic forms thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.

公开(公告)号：US20240051953A1

公开(公告)日：2024-02-15

申请号：US17965569

申请日：2022-10-13

Applicant: C4 Therapeutics, Inc.

Inventor： Christopher G. Nasveschuk ,  Rhamy Zeid ,  Ning Yin ,  Katrina L. Jackson ,  Gesine Kerstin Veits ,  Moses Moustakim ,  Jeremy L. Yap

IPC: C07D471/04 ,  C07D401/14 ,  A61P35/00

CPC classification number: C07D471/04 ,  A61P35/00 ,  C07D401/14

Abstract: BRD9 protein degradation compounds or pharmaceutically acceptable salts thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.

公开(公告)号：US11691972B2

公开(公告)日：2023-07-04

申请号：US17541035

申请日：2021-12-02

Applicant: C4 Therapeutics, Inc.

Inventor： Christopher G. Nasveschuk ,  Rhamy Zeid ,  Ning Yin ,  Katrina L. Jackson ,  Gesine Kerstin Veits ,  Moses Moustakim ,  Jeremy L. Yap

IPC: C07D471/04 ,  C07D401/14 ,  A61P35/00

CPC classification number: C07D471/04 ,  A61P35/00 ,  C07D401/14

Abstract: A BRD9 protein degrading compound of structure




or a pharmaceutically acceptable salt thereof is provided for the treatment of a disorder mediated by BRD9, including but not limited to abnormal cellular proliferation including cancer.

公开(公告)号：US20220098194A1

公开(公告)日：2022-03-31

申请号：US17541035

申请日：2021-12-02

Applicant: C4 Therapeutics, Inc.

Inventor： Christopher G. Nasveschuk ,  Rhamy Zeid ,  Ning Yin ,  Katrina L. Jackson ,  Gesine Kerstin Veits ,  Moses Moustakin ,  Jeremy L. Yap

IPC: C07D471/04 ,  C07D401/14 ,  A61P35/00

Abstract: BRD9 protein degradation compounds or pharmaceutically acceptable salts thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.

公开(公告)号：US12157735B2

公开(公告)日：2024-12-03

申请号：US17965569

申请日：2022-10-13

Applicant: C4 Therapeutics, Inc.

Inventor： Christopher G. Nasveschuk ,  Rhamy Zeid ,  Ning Yin ,  Katrina L. Jackson ,  Gesine Kerstin Veits ,  Moses Moustakim ,  Jeremy L. Yap

IPC: C07D471/04 ,  A61P35/00 ,  C07D401/14

Abstract: BRD9 protein degradation compounds or pharmaceutically acceptable salts thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.

公开(公告)号：US20240199581A1

公开(公告)日：2024-06-20

申请号：US18534395

申请日：2023-12-08

Applicant: C4 Therapeutics, Inc.

Inventor： Christopher G. Nasveshuk ,  Katrina L. Jackson ,  Yanke Liang ,  Robert T. Yu ,  Martin Duplessis ,  Mark E. Fitzgerald ,  Victoria Garza ,  Andrew Charles Good ,  Morgan Welzel O'Shea ,  Gesine Kerstin Veits ,  Cosimo Dolente ,  David Stephen Hewings ,  Daniel Hunziker ,  Daniela Krummenacher ,  Piergiorgio Franceso Tommaso Pettazzoni ,  Juergen Wichmann

IPC: C07D401/14 ,  A61P35/00 ,  C07D405/14 ,  C07D471/10 ,  C07D491/107 ,  C07D495/10

CPC classification number: C07D401/14 ,  A61P35/00 ,  C07D405/14 ,  C07D471/10 ,  C07D491/107 ,  C07D495/10

Abstract: The present invention provides compounds or their pharmaceutically acceptable salts and their pharmaceutical compositions that can be administered to a host such as a human in need thereof for the treatment of a disorder, such as cancer, mediated by mutant BRAF. The compounds efficiently degrade Class I, II and III mutant BRAF proteins.

公开(公告)号：US20230145336A1

公开(公告)日：2023-05-11

申请号：US18084380

申请日：2022-12-19

Applicant: C4 Therapeutics, Inc.

Inventor： Christopher G. Nasveschuk ,  Martin Duplessis ,  Mark E. Fitzgerald ,  Victoria Garza ,  Andrew Charles Good ,  Katrina L. Jackson ,  Yanke Liang ,  Moses Moustakim ,  Morgan Welzel O'Shea ,  Gesine Kerstin Veits ,  Jeremy L. Yap ,  Robert T. Yu ,  Cosimo Dolente ,  David Stephen Hewings ,  Daniel Hunziker ,  Bernd Kuhn ,  Piergiorgio Francesco Tommaso Pettazzoni ,  Fabienne Ricklin ,  Claus Riemer ,  Juergen Wichmann

IPC: C07D471/04 ,  C07D519/00

CPC classification number: C07D471/04 ,  C07D519/00

Abstract: Present invention provides compounds that cause specifically the degradation of BRAF. The present compounds are useful for the treatment of various cancers.